BICD2 Knockout HT29 Polyclonal Cells constitute a CRISPR/Cas9-edited polyclonal knockout cell population derived from the human HT29 colorectal adenocarcinoma line, designed to disrupt the BICD2 gene encoding a crucial adaptor protein for dynein-mediated retrograde transport. This polyclonal pool provides a mixed population of cells with targeted gene disruption, avoiding the clonal biases of single-cell-derived lines, and is suitable for studying the collective impact of BICD2 loss on intracellular trafficking and cellular organization.
HT29 cells are a widely utilized human colorectal adenocarcinoma cell line of epithelial origin, characterized by microvilli, mucin expression, and the capacity to differentiate upon sodium butyrate treatment. These cells serve as a robust model for intestinal epithelial barrier function and colon cancer biology, enabling investigation of processes such as polarity establishment, cell migration, and membrane trafficking in a pathophysiologically relevant context.
The BICD2 protein acts as an adaptor linking cargo, notably Rab6-associated vesicles, to the dynein motor complex via interactions with DYNC1H1 (dynein heavy chain) and DCTN1 (p150Glued). This interaction facilitates retrograde transport along microtubules, critical for Golgi apparatus positioning, mRNA localization, and nuclear migration. BICD2 is regulated by upstream factors including CDK1 and Rab6 GTPases, and its activity directly influences downstream processes such as Golgi organization and vesicle trafficking. Disruption of BICD2 function perturbs these pathways, leading to defective organelle distribution and transport, which is implicated in motor neuron diseases such as SMALED2 and hereditary spastic paraplegia.
In the HT29 background, BICD2 knockout provides a unique platform to dissect the role of retrograde transport in colorectal cancer cell biology, where Golgi integrity and polarized trafficking are essential for epithelial function and tumor progression. This model allows for the examination of how loss of BICD2-mediated transport affects cell polarity, migration, and response to extracellular cues, offering insights into the links between trafficking defects and oncogenic processes. Moreover, as HT29 cells differentiate and form barrier-like structures, the knockout system can be used to assess the contribution of BICD2 to epithelial organization and homeostasis.
Researchers can employ these BICD2 knockout polyclonal cells to study dynein-dependent retrograde transport using live-cell imaging of fluorescently tagged cargoes, immunofluorescence microscopy to assess Golgi morphology, and co-immunoprecipitation to probe protein interactions with the dynein complex. The polyclonal nature is advantageous for screening small molecules that modulate BICD2-associated pathways or for performing pooled functional genomics experiments. Additional applications include western blot analysis to confirm target protein loss, cell migration assays to evaluate motility changes, and complementation studies with mutant BICD2 variants linked to motor neuron diseases. This cell model thus serves as a versatile tool for investigations spanning cell biology, cancer biology, and neurobiology. For further information, please contact Ascent Research.
